Qiagen (QGEN) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $10.25B, a trailing price-to-earnings ratio of 20.6 and a free-cash-flow yield of 4.3%. Over the most recent reported fiscal year, revenue grew 5.7% and free cash flow per share fell 11.1%. Nama's AI scorecard rates it Buy, 6.8 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Buy · 6.8/10
Positive, at the low end of Buy. As of Nov 20, 2026.
Momentum
Middle · +9.5% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Shariah Compliant
Passes our debt, cash and income screen; not a scholar's ruling.
Off its high
-17.5%
How far the last close sits under the highest price of the past five years.
Market cap
$10.25B
Trailing P/E
20.6
Price / book
3.0
Price / sales
4.8
FCF yield
4.3%
Dividend yield
0.7%
Gross margin
62.8%
Operating margin
25.1%
Net margin
18.2%
Revenue growth (YoY)
+5.7%
Revenue growth (3-yr annual)
-0.8%
EPS growth (YoY)
+4.7%
FCF/share growth (YoY)
-11.1%
Beta
0.6
Exchange
NYSE
Sector
Healthcare
Industry
Diagnostics Research
QGEN earnings
Next report: Feb 3, 2027 (Q4 2026, EPS estimate $0.66).
Beat the EPS estimate in 1 of 4 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 3, 2026
$0.65
$0.63
+3.2%
$547.87M
Q2 2026
Aug 4, 2026
$0.60
$0.60
+0.0%
$535.04M
Q1 2026
May 5, 2026
$0.54
$0.54
+0.0%
$492.32M
Q4 2025
Feb 4, 2026
$0.62
$0.62
+0.0%
$540.42M
QGEN analyst price target
Median target $52.00 from 11 analysts, ranging $40.00 – $53.00.
Nama's AI scorecard currently rates Qiagen Buy (6.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is QGEN's P/E ratio?
Qiagen trades at a trailing price-to-earnings ratio of 20.6.
When does QGEN report earnings?
Qiagen's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $0.66.
What is the QGEN price target?
The median analyst price target from 11 analysts is $52.00, with a range of $40.00 – $53.00.
Is QGEN Shariah compliant?
Nama's AAOIFI-style screen reads Qiagen as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.